Calprotectin Testing Market is expected to reach US$ 348.2 Million by 2032 | FMI Analyst

The global Calprotectin Testing Market is expected to reach US$ 190.6 Mn in 2022, growing at a CAGR of 6.2% and surpassing US$ 348.2 Mn by the end of 2032. According to a recent study, calprotectin ELISA test kits would have a global market share of 91.3% in 2021.

Calprotectin is a fecal test, which is used to determine the inflammation in the intestines. The demand for calprotectin testing is increasing due to growing incidence of irritable bowel syndrome and cancer worldwide.

To read more about this report, visit @ https://www.futuremarketinsights.com/reports/calprotectin-testing-market

For instance, according to World Health Organization (WHO), approximately 1.93 million cases new cases of colon and recta cancer were registered in 2020 in the world.

In addition, focus on home testing is also boosting the market because home-based tests have various benefits such as ease of use and diagnosis. These tests can be easily conducted between patient visits if the condition is deteriorating and if more frequent testing is required.

This helps in planning a proper therapeutic plan that can be established by clinicians. Hence, several products from manufacturers are emerging to provide test kits for home testing.

Furthermore, the development of smart and advanced testing options in the market is also driving the market forward. For instance, IBSibs-smart is a testing kit that can be used in the detection of IBS biomarkers, anti-CdtB and anti-vinculin. It provides information related to IBS patients with diarrheal symptoms and can diagnose diarrhea-dominant or mixed-type IBS.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14504

Key players are involved in expanding their presence in the market through promotion, distribution and customer services related to their products for the betterment of the brand and products. Thus, boosting the demand for the product during the forecast period.

For instance, in January 2021, Actim Oy granted Ferring Pharmaceutical the rights to exclusively distribute Actim® PROM and Actim® Partus in the Mainland of China and to be responsible for the promotion, distribution and customer service.

Key Takeaways from Market Study

By testing kits, calprotectin ELISA test kits are expected to hold over 0% market value share by the end of 2032 and are expected to display a CAGR growth of 6.2% over the forecast period.
By sample, the stool is leading with over 0% of the market share in 2021 and is expected to hold a market value share of around 88.7% by 2032.
By indication, irritable bowel syndrome will showcase growth at a CAGR of 1% over the forecast period.
Based on end-user, hospitals held the highest segment share in terms of the market share value of 4% in 2021.
North America is considered to be the leading region with a value share of 4% at the end of the forecast period.

Have Conversation with Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-14504

"With increasing advancement in rapid test kits and point of care testing, the calprotectin testing market is expected to witness impressive growth over the forecast period," says an analyst of Future Market Insights.

Market Competition:

Collaboration among the companies or brands is the key strategy of the leading manufacturers of the market such as Calpro AS & Ampersand Health, Immunodiagnostic Systems Holdings, and Thermo Fisher Scientific to enhance their presence in the market and compete with other competitors during the coming years.

For instance:

In October 2021, Calpro AS & Ampersand Health collaborated to support self-management and remote monitoring of Inflammatory Bowel Disease (IBD).
In September 2021, Immunodiagnostic Systems Holdings and EUROIMMUN collaborated to enhance their field of research and development, production as well as distribution.
In September 2021, Thermo Fisher Scientific and AstraZeneca collaborated on the development of the next-generation sequencing (NGS)-based companion diagnostics (CDx) which support AstraZeneca's product portfolio.

Order a Complete Research Report @ https://www.futuremarketinsights.com/checkout/14504

Key Market Segments Covered in Calprotectin testing Industry Research

By Test Kits

Calprotectin ELISA Test Kits
Calprotectin Rapid Testing Kits

By Sample

Stool
Blood Serum/Plasma
Other Biological Samples

By Indication

Irritable Bowel Syndrome (IBS)
Ulcerative Colitis
Crohn's Disease
Colorectal Cancer

By End-User

Hospitals
Diagnostic Laboratories
Specialty Clinics

By Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports

This release was published on openPR.